References
- Augustine E, Mink J Neuronal Ceroid Lipofuscinosis. 2020 April 17 [cited 2020 Apr 24].
- Johnson TB, Cain JT, White KA, et al. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019 Mar;15(3):161–178.
- Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013 Sep;28(9):1142–1150.
- Levin SW, Baker EH, Zein WM, et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol. 2014 Aug;13(8):777–787.
- Augustine EF, Beck CA, Adams HR, et al. Short-term administration of mycophenolate is well-tolerated in CLN3 disease (Juvenile Neuronal Ceroid Lipofuscinosis). JIMD Rep. 2019;43:117–124.
- Palmieri M, Pal R, Nelvagal HR, et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun. 2017 Feb 6;8:14338.
- Cendret V, Legigan T, Mingot A, et al. Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent α-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors. Org Biomol Chem. 2015;13(43):10734–10744.
- Ghosh A, Rangasamy SB, Modi KK, et al. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 May;141(3):423–435.
- Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019 Oct 24;381(17):1644–1652.
- Lu J-Y, Nelvagal HR, Wang L, et al. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol Genet Metab. 2017 Sep-Oct;141(3):98–105.
- Schulz A, Ajayi T, Specchio N, et al. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med. 2018 May 17;378(20):1898–1907.
- Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol. 2016 Dec;21:75–80.
- Rietdorf K, Coode EE, Schulz A, et al. Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): more than a mere co-morbidity. Biochim Biophys Acta Mol Basis Dis. 2020 Sep 1;1866(9):165643.
- Katz ML, Johnson GC, Leach SB, et al. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression. Gene Ther. 2017 Apr;24(4):215–223.
- Cain JT, Likhite S, White KA, et al. Gene therapy corrects brain and behavioral pathologies in CLN6-Batten disease. Mol Ther. 2019 Oct 2;27(10):1836–1847.
- Mitchell NL, Russell KN, Wellby MP, et al. Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 Batten disease. Mol Ther. 2018 Oct 3;26(10):2366–2378.
- Bosch ME, Aldrich A, Fallet R, et al. Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3). J Neurosci. 2016 Sep 14;36(37):9669–9682.
- Shyng C, Nelvagal HR, Dearborn JT, et al. Synergistic effects of treating the spinal cord and brain in CLN1 disease. Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5920–E29.
- Sands MS. Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease). J Child Neurol. 2013 Sep;28(9):1151–1158.
- Lee BH, Collins E, Lewis L, et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1. Neurology. 2019 Oct 1;93(14):640–641.